An observational study in Hypercapnia, Asthma Exacerbation and COPD Exacerbation, sponsored by Centre Hospitalier Sud Francilien. Withdrawn at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by Centre Hospitalier Sud Francilien · Observational
The aim of this observational before/after study is to determine how to optimally administer oxygen to patients experiencing an asthma or COPD exacerbation in emergency medical services.
The aim will be to determine which method will achieve the target oxygen saturation objectives: > 95% in asthma exacerbations and between 88% and 92% (or > 92% in ambient air or with FiO2 21%) in COPD exacerbations.
The study will compare a group "before" receiving standard care with a nebulizer mask to a group "after" using a combination of a vibrating membrane nebulizer and high-flow nasal oxygen.
The "after" group will systematically receive both devices: vibrating membrane nebulizer and high-flow nasal oxygen.
In both groups, the choice of nebulized therapies will be left to the clinician's discretion.
156 studies on the registry are indexed under Hypercapnia; 31 are open to participants now.
Browse Hypercapnia studies →Centre Hospitalier Sud Francilien is the lead sponsor of 58 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients treated by the Corbeil-Essonnes SMUR (mobile emergency and resuscitation service) for acute exacerbation of COPD or asthma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment of exacerbation with nebulizer mask and oxygen therapy of 6 to 9 liters per minute
Device: nebulizer mask and oxygen therapy of 6 to 9 liters per minute
Treatment of the exacerbation by combining a vibrating membrane nebulizer and high-flow nasal oxygen, set with an FiO₂ between 21 and 100% and an O₂ flow rate between 30 and 70 liters per minute
Device: Vibrating membrane nebulizer and high-intensity nasal oxygen
Vibrating membrane nebulizer and high-intensity nasal oxygen
nebulizer mask and oxygen therapy of 6 to 9 liters per minute
Achievement of saturation targets
* Asthma: SpO₂ at 15 min \> 95% * COPD: SpO₂ at 15 min 88-92% or SpO₂ \> 92% in ambient air or with FiO₂ 21%
Time frame: at 15 minutes
FiO₂
Successful implementation of the vibrating membrane nebulizer and high-flow nasal oxygen devices
Time frame: at the end of care
flow rate
Successful implementation of the vibrating membrane nebulizer and high-flow nasal oxygen devices
Time frame: at the end of care
Likert scale
Likert scale on the ease of use of the device
Time frame: up to 30 minutes
Causes of failure
For the "after" group
Time frame: up to 30 minutes
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Sud Francilien